Belmont Global Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Belmont Global Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$15.7M	Buy	18,561 +2,528	+16%	+$2.03M	14.83%	1
2016 Q2	$13.2M	Buy	16,033 +5,500	+52%	+$5.99M	12.68%	2
2016 Q1	$11.7M	Buy	10,533 +4,033	+62%	+$4.13M	11.93%	2
2015 Q4	$8.1M	Buy	6,500 +3,833	+144%	+$6.34M	10.5%	2
2015 Q3	$3.6M	Buy	2,667 +1,295	+94%	+$2.14M	6.12%	3
2015 Q2	$2.47M	Buy	1,372 +1,153	+526%	+$1.79M	2.74%	6
2015 Q1	$354K	Sell	219 -852	-80%	-$1.26M	0.36%	63
2014 Q4	$815K	Buy	1,071 +166	+18%	+$88.1K	0.8%	35
2014 Q3	$358K	Buy	905 +167	+23%	+$80.5K	0.28%	90
2014 Q2	$446K	Buy	+738	New	+$411K	0.32%	83

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belmont Global Advisors's TCRT Position: Q3 2016 in Review

Belmont Global Advisors increased its Alaunos Therapeutics (TCRT) stake by 22% in Q3 2016, buying an estimated $2.18M and bringing the position to 14,835 shares worth $12.5M. The position accounts for 11.85% of the portfolio, ranked #3.

Belmont Global Advisors first reported a position in TCRT in Q4 2013 and has held it in 12 quarters since. The position peaked at $17.7M in Q2 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

Belmont Global Advisors held 14,835 shares of Alaunos Therapeutics worth $12.5M as of Q3 2016.
Belmont Global Advisors bought 2,715 Alaunos Therapeutics shares in Q3 2016, an estimated $2.18M.
Alaunos Therapeutics made up 11.85% of Belmont Global Advisors's portfolio in Q3 2016, its #3 holding.
Belmont Global Advisors first reported a position in Alaunos Therapeutics in Q4 2013 and has held it in 12 quarters since.
Belmont Global Advisors's Alaunos Therapeutics position peaked at $17.7M in Q2 2015.
140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.